To include your compound in the COVID-19 Resource Center, submit it here.

Kadmon reports Phase II data for IPF candidate

Kadmon Holdings Inc. (NYSE:KDMN) reported top-line data from the U.S. Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis (IPF) in patients previously treated with or offered Esbriet pirfenidone or Ofev nintedanib.

The company

Read the full 356 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE